WILMINGTON, Del. & SAN DIEGO--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) today announced that it has completed its acquisition of Escient Pharmaceuticals, a clinical-stage drug discovery and development company advancing novel small molecule therapeutics for systemic immune and neuro-immune disorders.

威尔明顿（WILMINGTON，Del.）和圣地亚哥（BUSINESS WIRE）——Incyte（纳斯达克：INCY）今天宣布，它已经完成了对Escient Pharmaceuticals的收购，Escient Pharmaceuticals是一家临床阶段的药物发现和开发公司，致力于推进用于全身免疫和神经免疫疾病的新型小分子疗法。

'The acquisition of Escient and its first-in-class oral MRGPR antagonists bolsters our Inflammation and Autoimmunity portfolio and our commitment to creating innovative solutions that address the urgent needs of patients living with severe inflammatory diseases,' stated Hervé Hoppenot, Chief Executive Officer, Incyte.

Incyte首席执行官HervéHoppenot表示：“收购Escient及其一流的口服MRGPR拮抗剂，增强了我们的炎症和自身免疫组合，以及我们致力于创造创新解决方案，以满足患有严重炎症性疾病的患者的迫切需求。”

'We are excited to continue the work started by the Escient team and accelerate the clinical development of these promising therapies.'.

“我们很高兴继续Escient团队开始的工作，并加速这些有前途的疗法的临床开发。”

Through this transaction, Incyte has added EP262 and EP547 to its portfolio. EP262 is a first-in-class, potent, highly selective, once-daily small molecule antagonist of Mas-related G protein-coupled receptor X2 (MRGPRX2). By blocking MRGPRX2 and degranulation of mast cells, EP262 has the potential to effectively treat multiple mast cell-mediated diseases including chronic inducible urticaria (CIndU), chronic spontaneous urticaria (CSU) and atopic dermatitis (AD).

通过此次交易，Incyte将EP262和EP547添加到其投资组合中。EP262是Mas相关G蛋白偶联受体X2（MRGPRX2）的一流，有效，高选择性，每日一次的小分子拮抗剂。通过阻断MRGPRX2和肥大细胞脱粒，EP262有可能有效治疗多种肥大细胞介导的疾病，包括慢性诱导性荨麻疹（CIndU），慢性自发性荨麻疹（CSU）和特应性皮炎（AD）。

EP547 is a first-in-class oral MRGPRX4 antagonist with the potential to treat cholestatic pruritus and other conditions with severe pruritus..

EP547是一流的口服MRGPRX4拮抗剂，有可能治疗胆汁淤积性瘙痒症和其他严重瘙痒症。

“Over the past six years, Escient has pioneered the characterization of MRGPR biology and advanced two novel candidates, EP262 and E547, into clinical development,” commented Joshua Grass, Chief Executive Officer of Escient Pharmaceuticals. 'The close of this transaction represents the recognition of value of the innovation by the Escient team, and also represents an exciting transition to Incyte, a global biopharmaceutical company that is well positioned to advance these novel candidates to address the unmet needs of patients worldwide.”.

Escient Pharmaceuticals首席执行官约书亚·格拉斯（JoshuaGrass）评论道：“在过去的六年中，Escient率先对MRGPR生物学进行了表征，并将两个新的候选药物EP262和E547推进了临床开发。”这笔交易的完成代表着Escient团队对创新价值的认可，也代表着向Incyte的令人兴奋的过渡，Incyte是一家全球生物制药公司，能够很好地推动这些新候选人解决全球患者未满足的需求。”

As previously disclosed, under the terms of the agreement, Incyte has acquired Escient and its assets for $750 million plus Escient’s net cash remaining at the close of the transaction, subject to customary adjustments.

如前所述，根据协议条款，Incyte以7.5亿美元的价格收购了Escient及其资产，外加Escient在交易结束时的剩余现金净额，但须按惯例进行调整。

Centerview Partners LLC and Goldman Sachs & Co. LLC advised Escient on the transaction, and Fenwick & West LLP acted as legal counsel for Escient. Covington & Burling LLP acted as legal counsel for Incyte.

Centerview Partners LLC和Goldman Sachs&Co.LLC为Escient提供交易咨询，Fenwick&West LLP担任Escient的法律顾问。Covington&Burling LLP担任Incyte的法律顾问。

About EP262

关于EP262

EP262 is a potent, highly selective once-daily small molecule antagonist of MRGPRX2, a receptor expressed on mast cells that is activated by numerous ligands, including many peptides released from sensory neurons as well as other cell types. In response to MRGPRX2 activation, mast cells release histamine, tryptase, chymase, chemokines and cytokines, which can cause itchy hives, angioedema, type 2 inflammation (through engagement of the adaptive immune system) and chronic pruritus and pain.

EP262是MRGPRX2的一种有效的，高选择性的每日一次的小分子拮抗剂，MRGPRX2是肥大细胞上表达的受体，被许多配体激活，包括从感觉神经元以及其他细胞类型释放的许多肽。响应MRGPRX2激活，肥大细胞释放组胺，类胰蛋白酶，糜蛋白酶，趋化因子和细胞因子，可引起荨麻疹，血管性水肿，2型炎症（通过适应性免疫系统的参与）和慢性瘙痒和疼痛。

Preclinical data demonstrate that, by blocking activation of MRGPRX2, EP262 has the potential to effectively treat a broad range of mast cell-mediated conditions, with an initial focus on chronic urticarias and atopic dermatitis..

临床前数据表明，通过阻断MRGPRX2的激活，EP262有可能有效治疗广泛的肥大细胞介导的疾病，最初的重点是慢性荨麻疹和特应性皮炎。

About EP547

关于EP547

EP547 is a potent, highly selective antagonist that blocks the activation of MRGPRX4 by various bile acids, bilirubin and urobilin. By virtue of this disease-specific mechanism of action, EP547 has the potential to be a highly targeted and efficacious treatment for cholestatic and uremic pruritus.

EP547是一种有效的高选择性拮抗剂，可阻断各种胆汁酸，胆红素和尿胆素对MRGPRX4的激活。凭借这种疾病特异性作用机制，EP547有可能成为胆汁淤积和尿毒症瘙痒症的高度靶向和有效治疗方法。

About Incyte

关于Incyte

A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity.

Incyte是一家全球生物制药公司，其使命是解决on问题，它遵循科学原理，为未满足医疗需求的患者寻找解决方案。通过专有疗法的发现、开发和商业化，Incyte为患者建立了一流的药物组合，并在肿瘤学、炎症和自身免疫领域建立了强大的产品线。

Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia..

Incyte总部位于特拉华州的威尔明顿，在北美、欧洲和亚洲都有业务。

For additional information on Incyte, please visit Incyte.com or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube.

有关Incyte的更多信息，请访问Incyte.com或在社交媒体上关注我们：LinkedIn、X、Instagram、Facebook、YouTube。

About Escient Pharmaceuticals

关于Escient Pharmaceuticals

Escient Pharmaceuticals is a clinical-stage company focused on developing novel therapeutics to address a broad range of neurosensory-inflammatory disorders. The company’s pipeline includes two first-in-class small molecule antagonists targeting MRGPRX2 for the treatment of various mast cell mediated disorders and MRGPRX4 for cholestatic pruritus.

Escient Pharmaceuticals是一家临床阶段公司，专注于开发新的治疗方法，以解决广泛的神经感觉炎症性疾病。该公司的管道包括两种一流的靶向MRGPRX2的小分子拮抗剂，用于治疗各种肥大细胞介导的疾病，以及MRGPRX4治疗胆汁淤积性瘙痒症。

Based in San Diego, California, Escient is led by an experienced management and scientific team and funded by top-tier life science investors..

Escient总部位于加利福尼亚州圣地亚哥，由经验丰富的管理和科学团队领导，并由顶级生命科学投资者资助。

Incyte Forward-Looking Statements

Incyte前瞻性声明

Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the opportunities presented by this transaction; whether and when EP262 or EP547 will be approved for use; whether and when Incyte will bring EP262 or EP547 to market; the potential of EP262 or EP547 to treat patients with atopic dermatitis (AD), chronic inducible urticaria (CIndU) and chronic urticaria (CSU) or for any other indication; and the potential for Incyte to broaden its ability to bring new medicines to patients, contain predictions, estimates and other forward-looking statements..

除此处所述的历史信息外，本新闻稿中所述的事项，包括有关本次交易带来的机会的声明；是否以及何时批准使用EP262或EP547；Incyte是否以及何时将EP262或EP547推向市场；EP262或EP547治疗特应性皮炎（AD），慢性诱导性荨麻疹（CIndU）和慢性荨麻疹（CSU）患者或任何其他适应症的潜力；Incyte有可能扩大其为患者带来新药的能力，包括预测、估计和其他前瞻性陈述。

These forward-looking statements are based on our current expectations and are subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials and the ability to enroll subjects in accordance with planned schedules; determinations made by the FDA and regulatory agencies outside of the United States; the efficacy or safety of our products; the acceptance of our products in the marketplace; market competition; unexpected variations in the demand for our products and the products of our collaboration partners; the effects of announced or unexpected price regulation or limitations on reimbursement or coverage for our products; sales, marketing, manufacturing, and distribution requirements, including our ability to successfully commercialize and build commercial infrastructure for newly approved products and any additional new products that become approved; and other risks detailed from time to time in our reports filed with the U.S.

这些前瞻性陈述基于我们目前的预期，并受到可能导致实际结果产生重大差异的风险和不确定性的影响，包括意外发展和与以下相关的风险：意外延误；进一步的研究和开发以及临床试验结果可能不成功或不足以满足适用的监管标准或需要继续开发；能够在临床试验中招募足够数量的受试者，并能够按照计划的时间表招募受试者；FDA和美国以外的监管机构做出的决定；我们产品的功效或安全性；我们的产品在市场上的接受程度；市场竞争；我们的产品和合作伙伴的产品需求出现意外变化；宣布或意外的价格法规或限制对我们产品的报销或保险范围的影响；销售、营销、制造和分销要求，包括我们成功商业化和为新批准的产品和任何其他获得批准的新产品建立商业基础设施的能力；以及我们向美国提交的报告中不时详述的其他风险。

Securities and Exchange Commission, including our annual report on Form 10-K and our quarterly report on Form 10-Q for the quarter ended March 31, 2024. We disclaim any intent or obligation to update these forward-looking statements..

美国证券交易委员会（SEC），包括截至2024年3月31日的10-K表年度报告和10-Q表季度报告。我们不承担更新这些前瞻性声明的任何意图或义务。